UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): May 26, 2017
 
Pharma-Bio Serv, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
0-50956
20-0653570
(Commission File Number)
(I.R.S. Employer Identification No.)
 
6 Road 696, Dorado, Puerto Rico
00646
(Address of Principal Executive Offices)
(Zip Code)
 
(787) 278-2709
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders.
 
On May 26, 2017, Pharma-Bio Serv, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders. Below is a summary of the proposals and corresponding votes.
 
Irving Wiesen was elected as a Class I director to serve for a term until the 2020 Annual Meeting of Stockholders or until a successor is duly elected and qualified. Irving Wiesen received the following votes:
 
Nominee
 
For
 
Withheld
Irving Wiesen
 
11,341,493
 
777,800
 
There were 4,211,404 broker non-votes on this proposal.
 
The ratification of the selection of Horwath Velez & Co. PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2017 received the following votes:
 
For
 
Against
 
Abstain
16,282,897
 
47,800
 
-
 
There were no broker non-votes on this proposal.
 
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
PHARMA-BIO SERV, INC.
 
 
 
 
 
Date: May 31, 2017
By:
/s/ Pedro J. Lasanta
 
 
 
Pedro J. Lasanta
 
 
 
Chief Financial Officer, Vice President Finance and Administration and Secretary
 
 
 
 
 
 
 

 3